Special Consultant Surgeons, Yodogawa Christian Hospital, Osaka, Japan.
Expert Rev Anticancer Ther. 2019 Nov;19(11):939-945. doi: 10.1080/14737140.2019.1685877. Epub 2019 Nov 22.
: Today, there is a global consensus that adjuvant treatment is mandatory for stage II and III gastric cancer. What remains controversial, however, is what constitutes the best adjuvant therapy. A comprehensive review including published papers, doi documents, and abstracts from the ASCO annual meeting was undertaken to develop this updated review.: Adjuvant treatments for stage II or more advanced and potentially curable gastric and gastroesophageal junction (GEJ) adenocarcinoma are, exclusively, reviewed and discussed.: The role of radiation is not yet established for gastric and GEJ cancers. Postoperative chemoradiotherapy offers no survival advantage over chemotherapy alone for patients who undergo D2 surgery. It is not yet clear if neoadjuvant chemoradiotherapy is better than adjuvant chemotherapy. Individualized treatment plans should be determined for many patients as efficacy depends on tumor histology, and toxicity varies enormously among effective options.
: 目前，全球共识认为辅助治疗对于 II 期和 III 期胃癌是强制性的。然而，仍存在争议的是，何种治疗方案是最佳的辅助治疗。本综述对已发表的论文、doi 文件以及 ASCO 年会摘要进行了全面回顾，以更新该综述：专门对 II 期或更晚期且有潜在治愈可能的胃和胃食管交界处（GEJ）腺癌的辅助治疗进行了回顾和讨论。：对于胃和 GEJ 癌症，放射治疗的作用尚未确定。对于接受 D2 手术的患者，术后放化疗并不能比单独化疗带来生存优势。目前尚不清楚新辅助放化疗是否优于辅助化疗。对于许多患者，应制定个体化的治疗计划，因为疗效取决于肿瘤组织学，而有效治疗方案之间的毒性差异非常大。
